CLINICAL TRIALS PROFILE FOR RAMUCIRUMAB
✉ Email this page to a colleague
Biosimilar Clinical Trials for ramucirumab
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT03766607 ↗ | Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer | Withdrawn | Korean South West Oncology Group | Phase 2 | 2019-09-30 | The aim of this study is to evaluate the efficacy and safety of combination therapy with ramucirumab, paclitaxel, and trastuzumab biosimilar as second line treatment of HER2 positive metastatic gastric cancer after failure of first line chemotherapy including trastuzumab. This study is a phase II, single-arm, open label, multi-center study. |
| NCT05800418 ↗ | Clinical Study to Compare the Pharmacokinetics and Safety of Ramucirumab Injection With Cyramza ® in Healthy Male Volunteers | Completed | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1 | 2019-11-04 | Ramucirumab is a biosimilar drug of CYRAMZA® produced by Chiatai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., LTD. It is a vascular endothelial growth factor receptor 2 (VEGFR-2) antagonist. This single-center, randomized, double-blind, single-dose, parallel phase I study of Ramucirumab injection versus Cyramza ® in healthy male volunteers was designed to evaluate the similarities in pharmacokinetics, tolerance, safety and immunogenicity of Ramucirumab and CYRAMZA®. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for ramucirumab
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00533702 ↗ | A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma | Completed | Eli Lilly and Company | Phase 2 | 2007-11-01 | The primary objective of this study is to determine the progression-free survival (PFS) of participants with previously untreated metastatic malignant melanoma when treated with IMC-1121B (ramucirumab) alone or in combination with dacarbazine. |
| NCT00683475 ↗ | A Study of IMC-A12 or Ramucirumab Plus Mitoxantrone and Prednisone in Prostate Cancer | Completed | Eli Lilly and Company | Phase 2 | 2008-08-01 | The purpose of this study is to determine whether IMC-A12 or IMC-1121B (ramucirumab) with Mitoxantrone and Prednisone is effective in the treatment of metastatic androgen- independent prostate cancer (APIC). |
| NCT00703326 ↗ | Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer | Completed | Eli Lilly and Company | Phase 3 | 2008-08-06 | The objective of this study is to compare the progression-free survival (PFS) of the drug combination ramucirumab plus docetaxel to placebo plus docetaxel in previously untreated participants with human epidermal growth factor receptor 2 (HER2)-negative, unresectable, locally-recurrent or metastatic breast cancer. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ramucirumab
Condition Name
Clinical Trial Locations for ramucirumab
Trials by Country
Clinical Trial Progress for ramucirumab
Clinical Trial Phase
Clinical Trial Sponsors for ramucirumab
Sponsor Name
